Purpose To assess the long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for partial seizures in adults with newly diagnosed epilepsy.
Method Adult patients completing a Phase III, randomised, double-blind, non-inferiority trial comparing zonisamide versus carbamazepine monotherapy entered a long-term extension study, continuing the same treatment (zonisamide, N=137; carbamazepine, N=158). Dose ranges were zonisamide 200–500 mg/day and carbamazepine 400–1200 mg/day. Safety assessments included treatment-emergent adverse events (TEAEs) and clinical laboratory parameters. Efficacy assessments included retention and seizure freedom rates.
Results Overall incidence of TEAEs was similar for zonisamide (52.6%) versus carbamazepine (46.2%). Most TEAEs (>95%) were of mild or moderate intensity; the most commonly reported being decreased weight (5.8% vs. 0%) and headache (4.4% vs. 6.3%). Incidences of serious treatment-related TEAEs and TEAEs leading to withdrawal were low and similar between groups (0.7% vs. 1.9% and 1.5% vs. 0.6%, respectively). There were small-to-moderate decreases in bicarbonate levels from baseline in the zonisamide group (mean -3.4 mmol/L). Vital signs and physical/neurological examinations identified no safety concerns. Retention rates for zonisamide versus carbamazepine were generally similar at all time-points (58.4% vs. 61.4%, 27.7% vs. 27.8% and 5.8% vs. 2.5% at 12, 18 and 24 months, respectively; intent-to-treat population). Seizure freedom rates after 24 months of treatment were 32.3% versus 35.2% (zonisamide vs. carbamazepine; intent-to-treat population).
Conclusion Zonisamide monotherapy demonstrated favourable long-term safety and maintenance of efficacy when used to treat partial seizures in adults with newly diagnosed epilepsy. No new or unexpected safety findings emerged.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.